OR WAIT null SECS
CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about clinical benefits of using mobocertinib in patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer.
At the 2021 World Conference on Lung Cancer, CancerNetwork® spoke with Alexander Spira, MD, PhD, FACP, of Virginia Cancer Specialists, about how mobocertinib led to antitumor activity in patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer (NSCLC) who were treated in a phase 1/2 study (NCT02716116) following prior tyrosine kinase inhibitor (TKI) therapy.
This is a subset analysis of a study of mobocertinib that has been going on for quite some time. It started as a phase 1 study, and this looked at a specific population of patients who got prior TKI therapy against [EGFR] exon 20. [Prior therapy] included experimental drugs, [such as] afatinib [Gilotrif], osimertinib [Tagrisso], and other [EGFR] exon 20 drugs like poziotinib. [The goal of the study was to] see how well [patients] did when they were treated with mobocertinib.
What we learned from this study is that patients who got prior TKI were able to benefit from mobocertinib, which was good news. Some of these TKIs were specific against [EGFR] exon 20, such as poziotinib, while others were not necessarily [EGFR] exon 20 specific, but more broad TKIs such as afatinib or osimertinib. My take home on this is that there is at least some evidence of efficacy of mobocertinib in patients who got other TKIs prior [to treatment] so we’re hoping that mobocertinib serves as a best in class compared to the other TKIs that are out there.
Spira A, Ramalingam SS, Neal J, et al. Mobocertinib in EGFR exon 20 insertion-positive metastatic NSCLC patients with disease control on prior EGFR TKI therapy. Presented at: 2021 World Conference on Lung Cancer; September 8-14, 2021. Virtual. Abstract OA15.01.